KRAS and non-small cell lung carcinoma: The recent Food and Drug Administration approval of the KRAS G12C-selective inhibitor sotorasib44 in KRAS G12C-mutant non-small cell lung cancers (NSCLCs) represented a milestone in treating KRAS-driven cancers.